PFG Investments LLC bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 3,274 shares of ...

While Russell 2000 lags major indexes, Dave, GeneDx, Root lead small-cap stocks with massive gains. Which small cap stocks to ...

Craig-Hallum analyst William Bonello maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today. The company’s shares closed ...

Nisa Investment Advisors LLC grew its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 147,085.3% ...

Key Insights Institutions' substantial holdings in GeneDx Holdings implies that they have significant influence ...

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

GeneDx has made "important" product improvements to its rapid whole-genome sequencing (rWGS) product in 2024 that should help it unlock genomic testing in the neonatal intensive care unit setting, CEO ...

STAMFORD, Conn. - GeneDx Holdings Corp. (NASDAQ:WGS), known for its genomic insights in healthcare and having achieved an impressive 2,342% return over the past year according to InvestingPro data, ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...